Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?

被引：0
|
作者：
Khaki, Ali Raza [1 ,4 ]
Lythgoe, Mark P. [2 ]
Prasad, Vinay [3 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Imperial Coll London, London, England
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Stanford Univ, Sch Med, Clin E, 875 Blake Wilbur Dr, Stanford, CA 94305 USA
来源：
JOURNAL OF CANCER POLICY | 2023年 / 35卷
关键词：
ONCOLOGY;
D O I：
10.1016/j.jcpo.2023.100402
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The effect of immediate breast reconstruction on adjuvant therapy delay, locoregional recurrence, and disease-free survival
    Grigor, Emma J. M.
    Stein, Michael J.
    Arnaout, Angel
    Ghaedi, Bahareh
    Cormier, Nicholas
    Ramsay, Tim
    Zhang, Jing
    BREAST JOURNAL, 2021, 27 (12): : 857 - 862
  • [42] Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (03): : 277 - +
  • [43] Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival
    Ossato, Andrea
    Gasperoni, Lorenzo
    Del Bono, Luna
    Messori, Andrea
    Damuzzo, Vera
    CANCERS, 2024, 16 (03)
  • [44] Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer
    Arden, Jessica D.
    Marvin, Kimberly
    Ye, Hong
    Juratli, Lena
    Nandalur, Sirisha R.
    Al-Wahab, Zaid
    Field, Jayson
    Gadzinski, Jill
    Rakowski, Joseph Anthony
    Rosen, Barry
    Jawad, Maha Saada
    ADVANCES IN RADIATION ONCOLOGY, 2020, 5 (06) : 1232 - 1239
  • [45] The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer
    Andrea Bever
    Jackie Manthorne
    Tissa Rahim
    Layla Moumin
    Shelagh M. Szabo
    The Patient - Patient-Centered Outcomes Research, 2022, 15 : 307 - 316
  • [46] The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer
    Bever, Andrea
    Manthorne, Jackie
    Rahim, Tissa
    Moumin, Layla
    Szabo, Shelagh M.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2022, 15 (03): : 307 - 316
  • [47] Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006
    Ng, R.
    Pond, G. R.
    Tang, P. A.
    MacIntosh, P. W.
    Siu, L. L.
    Chen, E. X.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 481 - 486
  • [48] Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis
    Ajani, Jaffer A.
    Leung, Lisa
    Singh, Prianka
    Kurt, Murat
    Kim, Inkyu
    Pourrahmat, Mir-Masoud
    Kanters, Steve
    EUROPEAN JOURNAL OF CANCER, 2022, 170 : 119 - 130
  • [49] Disease-free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant therapy
    Duska, Linda
    Prabhu, Vimalanand
    Kponee-Shovein, Kale
    Song, Yan
    Chen, Lei
    Cheng, Mu
    Sun, Yezhou
    Hilts, Annalise
    Hua, Qi
    Lichfield, Jasmine
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S289 - S289
  • [50] Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival
    Zaniboni, A
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2432 - 2441
12345